Scholars Central

Conference abstractPublished 2 Sep 2016

Guidelines for engineering of probiotics

Authors: Rob te Biesebeke

InnovationWorks, Switzerland

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Recent research has suggested that probiotics exert a wide range of effects through different mechanisms and sites of action, dependent on the host. Although the European Food Safety Agency has evaluated current probiotic strains insufficient characterized and clinical research ample for health claim approval, consumers (e.g., in the US) are interested in potential therapeutic and preventive health benefits. The Food and Agriculture Organization of the United Nations and the World Health Organization provide guidelines for probiotics: Proper identification to the level of strain of all probiotics in the product, with deposit of all strains in an international culture collection; Characterization of each strain for traits important to its safety and function; Validation of health benefits in human studies, including identification of the quantity of the microorganism required to provide the benefit and; Truthful and not misleading labeling of efficacy claims and content through the end of shelf life. Over the last years we have seen examples of genetically modified strains with adapted physiological properties compared to the parenteral strain and these provide a start for prosperous future developments. The genetic modifications can impact improved survival/retention in the gastrointestinal tract, cell cycle, cell wall, antibiotic resistance and biochemical/metabolic properties of the strains. The current guidelines that any strain of microorganism that would be assigned to a group would be freed from the need for further safety assessment is insufficient to guarantee any health impact in short and long term. It is therefore crucial that improved guidelines allow flexible developments to secure quality and safety, specifically when it concerns infants and premature infants or metabolically compromised individuals and when it concerns the possible long-term effects.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Biotechnology & Biomaterials.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Biotechnology & Biomaterials
  • SubjectBiochemistry & Biotechnology
  • SubjectMaterials Science
  • BylineArticles whose byline prints “Rob te Biesebeke”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels